Qualitative Analysis of the Roles of Physicians and Nurses in Providing Decision Support to **Patients With Relapsed or Refractory** Leukemia and Lymphoma

Cancer Control Volume 29: 1-9 © The Author(s) 2022 Article reuse guidelines: sagepub.com/iournals-permissions DOI: 10.1177/10732748221131003 journals.sagepub.com/home/ccx (S)SAGE

Miharu Morikawa¹ and Yuki Shirai²

Abstract

Introduction: This study examined the roles of hematologists and other professionals in providing decision support to patients with relapsed or refractory leukemia and lymphoma.

Methods: This was a qualitative study using in-depth semi-structured interviews involving 11 hematologists in Japan.

Result: We identified 7 categories related to the roles of hematologists in providing direct decision support to patients: (1) preparing patients before informed consent, (2) selecting the information to convey, (3) choosing a method for conveying this information, (4) respecting the intentions of patients and their families, (5) directing decision-making and considering fairness, (6) considering the emotional aspects of patients and their families, and (7) providing support after discussing treatment options. We also identified the following 5 subcategories related to the roles of hematologists in multidisciplinary collaboration: (1) communicating with other professionals, (2) gathering information from them, (3) providing information to them, (4) managing the entire medical team, and (5) encouraging nurses to actively participate with patients throughout the decision-making process.

Conclusion: Through content analysis, the hematologist's direct role in decision-making was extracted as preparation and consideration in situations where information about decision-making is communicated, and emotional support after the information is communicated. In addition, active participation in discussions, sharing information about the patient's situation and relevant discussions, and emotional support as the hematologist's expected roles in other professions were extracted. The results therefore suggest that a multidisciplinary team is needed to share information and provide multidimensional support to patients.

Keywords

hematologic diseases, shared decision-making, patient care team, physician's role, communication

Received May 2, 2022. Received revised August 3, 2022. Accepted for publication September 5, 2022.

Introduction

The prognosis and illness trajectory of leukemia and lymphoma vary greatly depending on the degree of progression and subtype of the disease. However, irrespective of the illness trajectory, patients face the same issues and debates related to decision-making, such as how far to go with aggressive treatment during the relapse or treatment-resistant period and ¹Otakanomori Chirdren's Clinic, Chiba, Japan ²Department of Human Health Sciences, Kyoto University, Kyoto, Japan

Corresponding Author:

Yuki Shirai, Department of Human Health Sciences, Kyoto University, 53 Shougoinkawaharacho, Kyoto Sakyo-ku, 606-8507 Kyoto, Japan. Email: shirai.yuki.6r@kyoto-u.ac.jp



Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

the choice of treatment and place of care.¹⁻³ Even in relapse cases, such patients may have the option to receive high-dose chemotherapy treatments or hematopoietic cell transplantations aimed at remission and achieving long-term survival. Such treatment carries significant risks, including complications such as severe infections and bleeding due to bone marrow suppression and treatment-related death, and may result in transition from invasive treatment aimed at cure to end-of-life (EOL). Even when the disease is refractory to treatment, anticancer therapy aimed at disease control is often administered until the end of life. In such contexts, it is very difficult for patients and their families to make decisions about these complex treatment strategies and the high risks involved in the context of their own life values.⁴⁻⁶

The American Society of Clinical Oncology (ASCO) has published consensus guidelines for clinician-patient communication, specifically recommending that clinicians provide information that is congruent with their patients' interests and intentions while jointly considering their goals for treatment.⁷ It is also notable that hematologists' communication skills have been receiving increasing attention in hematology clinical practice in recent years. An ethnographic study of hematologists' communication patterns when communicating bad news revealed 4 characteristics: (1) technical-defensive patterns, (2) an authoritative pattern, (3) a relational-recursive pattern, and (4) a compassionate sharing pattern, and the paper also suggested that hematologists were not good at expressing caring and empathy.⁸ In contrast, a qualitative study examining the needs of patients with hematological malignancies when being told bad news reported identifying emotional support from their healthcare providers and information needs about future support systems. It was also noted that healthcare-team involvement is necessary to meet these patients' needs and support their decision-making.9

Therefore, this study sought to clarify the following: (a) the way in which hematologists perceive the roles of doctors in providing decision-making support to patients suffering from relapsed and refractory leukemia as well as lymphoma, (b) the expected roles of hematologists in supporting decisionmaking via multidisciplinary collaboration, and (c) the roles hematologists expect other healthcare providers to fulfill.

Methods

The purpose of this study was to determine hematologists' role in decision support for patients with leukemia and lymphoma. Physicians at institutions with hematology wards and hematology outpatient clinics where chemotherapy and bone marrow transplantation are performed were included. The eligibility criteria for physicians included being Board Certified Hematologists and having at least 5 years of experience. Hematologists meeting these criteria were considered to have experience seeing patients with relapsed or refractory leukemia or lymphoma. Subjects were selected using opportunistic sampling, which is used in selecting those with common characteristics and the potential to provide a rich, appropriate, and diverse research agenda. Eligible physicians were asked to recommend a qualified physician who met the inclusion criteria to the head of the hematology department of a hospital in Tokyo. The recommended physicians were informed orally and in writing about the purpose and methods of the study and the voluntary participation clause. Although this is a qualitative study and it is difficult to theoretically calculate the sample size, we chose a sample size of 10 to 15 participants based on previous studies⁹⁻¹¹ using the same content analysis method as in this study. The acceptance rate of recommended physicians was 100%.

Verbal and written explanations of the research objectives and procedures were provided to all participants, and written consent was obtained. This study was approved by the Institutional Review Board of University of Tokyo (Approval No. 3443). The study was initiated at the University of Tokyo and completed at Kyoto University.

To collect the data, we conducted in-depth interviews to identify the attributes and roles of doctors as well as the expected roles of nurses in providing decision-making support to patients with relapsed or refractory leukemia and lymphoma. Specifically, we scheduled face-to-face semistructured interviews in private rooms between August and December 2011. All the interviews conducted were audio recorded and fully transcribed by 1 researcher (a research nurse), who also took detailed field notes during each interview. Physicians were first asked for their demographic details, including age, the type of facility where they worked, and the number of years they had worked in their area of specialization. We then asked them about their roles in treating patients suffering from relapsed or refractory leukemia and lymphoma.

To analyze the data, interview data were transcribed verbatim from the audio recordings. Interview data were then numbered for each participant, separated from personal information, and anonymized. A content analysis was then conducted. First, 1 researcher extracted all statements related to the 3 study topics from each transcript (eg, the role of hematologists, the role of hematologists in multidisciplinary collaboration, and the expectations of other professionals in the context of providing decision-making support). We then carefully conceptualized the text and categorized it into content areas through content analysis using the Klaus Krippendorff¹² method. The units, codes, and categories were decided through consensus. Next, another experienced qualitative researcher read the original interviews and classified them into categories and subcategories. The coder read the original interview text and independently determined the subcategory into which the content fell. The rate of agreement between the researchers and coders was 91%. Finally, the coder and the researcher discussed the units they disagreed on until they reached a consensus.

Results

Participant Characteristics

We conducted semi-structured interviews involving 11 hematologists. The average participant age was 44 years (range: 35-54 years), whereas the average specialization experience was 16 years (range: 7-26 years). Additional details are listed in Table 1. The average length of the interviews was 27 minutes (range: 17-46 minutes).

The Role of Hematologists in Direct Decision Support

As shown in Table 2, we identified 7 categories related to hematologists' roles in providing direct decision support to patients: (1) preparing patients before informed consent, (2) selecting the information to convey, (3) choosing a method for conveying this information, (4) respecting the intentions of patients and their families, (5) directing decision-making and considering fairness, (6) considering the emotional aspects of patients and their families, and (7) providing support after discussing treatment options.

Preparing Patients Before Informed Consent (IC). This category comprised 4 subcategories. Several participants talked about preparing patients and families for IC discussions, including "Gathering preliminary information for explaining issues to patients" and "Encouraging family members to participate in decision-making." As such, physicians were expected to prepare patients before IC discussions. For instance, they would provide patients with information regarding the risk of relapse.

Selecting the Information To Convey. This category comprised 3 subcategories. In subcategory (1) "Choice of information to provide to patients," more than half of the participants said that they did not provide their patients with prognoses. More importantly, more than half said they may not even tell their patients the truth, depending on the severity of the illness, to

Table I. Characteristics of doctors and interview details.

		Hematologists
Total		n = 11
Gender		
_	Male	10
	Female	I
Workplace		
	University hospital	7
	Cancer center	2
	General hospital	2
Age (years)	-	43.9 (34-54)*
0 0 /	n specialty (years)	16.1 (7-26)*

*Mean(Range).

avoid a loss of hope; they were very selective about the information they chose to provide to their patients.

In subcategory (2) "Providing patients and families with information to help them make treatment decisions," more than half of the participants identified "Communicating the advantages and disadvantages of treatment options" and "Telling patients and their families the information they need to make treatment decisions." They provided information they believed would help patients and their families fully understand all the options before making a final decision.

In subcategory (3), "Providing patients and families with information to help them understand the patients' current situation," a large number said they would inform family members about the possibility of sudden changes and specific prognoses, with more than half saying they would explain the issues so that patients could visualize what may happen to them in the future. Generally, participants provided information to help patients and their families clearly understand their current situations.

Choosing the Way In Which To Communicate Information. This category comprised 2 subcategories. Nearly half of participants expressed the ideas of "I determine what I say and how I say it based on our long-standing relationship with the patients" and "Providing information based on the patient's reaction and acceptance of their medical condition." They carefully considered what they discussed and how they discussed it, especially considering their long-standing association with their patients. In this regard, they conveyed information based on how they thought patients would react and their level of acceptance. They also provided explanations according to what they believed patients intended and thought depending on their respective stages of readiness. Moreover, nearly half said that they would explain issues without using jargon, thereby ensuring that the information provided was easy to understand. Essentially, participants remained cognizant of the need to communicate both correctly and appropriately with patients and their families.

Respect for The Intentions Of Patients And Families. This category comprised 2 subcategories. In subcategory (1) "Respect for the will of patients and families," more than half of the participants said they helped patients and families make decisions by supporting and respecting their wishes and desired treatments. In subcategory (2) "Setting goals in accordance with the preferences of the patients and families," several participants said that they helped patients and families set feasible goals after listening to their wishes.

Directing decision-making and considering fairness. This category comprised 2 subcategories. In subcategory (1) "Considering the direction and fairness of treatment options recommended by doctors," more than half of the participants said they explain treatment options with some direction while also providing options they find most beneficial. They talked about

	Category		Subcategory	Code	r
I	Preparing patients before IC*	(I)	Gathering preliminary information for explaining issues to patients	Obtain information from family members to understand the patient's preferences in advance	
				Check if home care is possible	
				Understand the family background	
		(2)		Talk to the family about what you will tell the patient	
		(2)	Encouraging family members to participate in decision-making	Set up a place to provide information to patients, including family members	
				Discuss life-prolonging treatments with the patient's family	
		(3)	Creating an environment for concentrating	Discuss in a private room	
			on IC	Take sufficient time Leave the PHS* 2 with the nurse so that the discussion	i
				is not disturbed	
		(4)	Providing advance information on the risk of relapse	When the patient reaches complete remission, explain the risk of relapse and prepare the patient for relapse	
2	Selecting the information to convey	(I)	Choice of information to provide to patients	In many cases, do not give the patient a prognosis Depending on the patient's medical condition, I (doctor) may not tall the truth	
				(doctor) may not tell the truth Modify the message according to the patient's life stage	
		(2)	Providing patients and families with information to help them make treatment	Communicate the advantages and disadvantages of treatment options	
			decisions	Tell patients and their families the information they need to make treatment decisions	
				Inform patients of all treatment options	1
				Communicate not only the bad news, but also ways of improvement	
				Also convey the option of non-treatment	
		(3)	Providing patients and families with information to help them understand the patients' current situation	Inform family members about the possibility of sudden changes in the medical condition and specific prognosis	
			patients current situation	Provide patients with information related to what	
				they imagine will happen in the future Provide patients with information that will help them	
				understand their current medical condition	
				Provide patients with a vague idea of their prognosis	
				Communicate the prognosis to patients using concrete numbers	
3	Choosing how to communicate information	(1)	Explanations based on the patients' stage of readiness	Judge what I (doctor) say and how I (doctor) say it based on long-standing relationship with the patients	
				Provide information based on the patient's reaction and acceptance of their medical condition	
		(2)	Respect for the preferences of patients and their families		
				Provide explanations so that patients/families do not develop misconceptions	: 4
				Convey information carefully and clearly	1
				Provide a written explanation	2
				Divide bad news into components	I

Table 2. Role of hematologists in providing direct decision support (n = 11).

(continued)

Table 2. (continued)

Category		Subcategory	Code	n
4 Respect for the intentions of patients and families	(I)	Respect for the will of patients and families	Respect and support the patient's will and desired treatment	6
			If the patient's condition is severe, respect the views of the family and primary caregiver	2
	(2)	Setting goals in accordance with the preferences of the patients and families	Listen to the needs of patients and their families and determine actionable treatment goals	3
			Explore the intentions of patients and their families through conversations	Ι
			If there is no difference between the advantages and disadvantages of a treatment choice, the choice is purely made by the patient	
5 Directing decision-making and considering fairness	(1)	Considering the direction and fairness of treatment options recommended by doctors	Explain treatment options with some direction while also providing options that the doctor finds beneficial	8
			In some cases, offer personal opinion as a doctor	2
			Dare to treat the patient with paternalism	2
	(2)	Consideration for patients to make impartial decisions	Communicate with the knowledge that the doctor's manner of speaking influences the patients' decisions	5
			Explain the opinions of other doctors and the second opinion system	I
6 Considering the emotional	(I)	Explaining with consideration for emotions	Talk in a way that allows the patient to have hope	5
aspects of the patient and family			Convey bad news according to the protocol Consider that patients do not have to listen to explanations while always looking at bad information	I
			Divulge bad news in stages	
	(2)	Showing a supportive attitude to the patient	Approach the patient with a non-abandoning attitude	2
	(2)		Show that the team supports the patient	1
	(3)	Attitude when facing patients and their	Interact with patients on an equal footing	2
		families	Talk while looking into the patient's eyes	
	(1)		Interact with the patient's family on an equal footing	
7 Supporting after discussing treatments	(1)	Emotional support after discussing treatments	Support fluctuations in the patient's mind after discussing treatments	2
			Call out the family and assess their reactions	I

*¹IC = informed consent; *²PHS = Personal Handyphone System (A phone used by doctors to communicate with staff in the hospital).

giving weight to treatment options and facilitating the decision-making process. Furthermore, they attempted to present information in a fair manner, being aware that the way they talk can affect the way patients perceive their treatment, as shown in subcategory (2).

Considering the Emotional Aspects Of The Patient And Family. This category comprised 3 subcategories. In subcategory (1)"explaining with consideration for emotions," nearly half of the participants said they would attempt to instill hope among patients, and hence, provide explanations considering the related emotional aspects. In subcategory (2) "showing a supportive attitude to the patient", several participants also expressed adopting a supportive stance to reassure patients that they were not abandoning them or their families. In subcategory (3) "attitude when facing patients and their families", several participants talked about the doctor's attitude toward patients, such as speaking with patients and families as equals and looking them in the eye.

Providing support after discussing treatments. Several participants said they informed patients about bad news and future treatments, after which they provided emotional support in consideration of any emotional variabilities.

Role of Hematologists in Multidisciplinary Collaboration and Providing Decision Support

We identified the following 5 subcategories related to the second main study topic—the roles of hematologists in multidisciplinary collaboration: (1) communicating with other professionals, (2) gathering information from them, (3) providing information to them, (4) managing the entire medical team, and (5) encouraging nurses to actively participate with

patients throughout the decision-making process (Table 3). More than half of the participants recognized the hematologist's role in communicating with other professionals and obtaining information about the patient (eg, the patient's background and how to help) throughout this process. Others said that they actively encourage nurses to support the patients' decisions and provide additional information during the discussions or explain the prognoses and future treatment plans to other professionals.

Expected Roles of Other Professionals in Providing Decision Support

We extracted the following 4 categories related to the roles that hematologists expected other professionals to fulfill: (1) sharing patient information and care routines, (2) sharing information from treatment discussions, (3) providing emotional support to patients and their families, and (4) assembling a medical team that understands hematological malignancies (Table 4). Nearly half of the participants indicated that they would like other health care providers to convey the patients' thoughts and intentions that they knew to the doctors involved. They also expected other professionals to share information regarding their patients and the way in which they cared for their patients.

Discussion

In this study, hematologists were interviewed to clarify their role and expectations of other professionals. The categories of hematologists' direct role in decision-making were extracted, including preparation and consideration of the situation in which information about decision-making is communicated and emotional support after the information is communicated.

Hematologists presented treatment options based on a variety of factors, including the patient's goals, emotions, the preparedness for the disease, and the severity of the disease. During this process, the hematologists worked with other professionals to understand specific information about the patient and family, including their background, goals, and

Table 3. The role of hematologists in multidisciplinary collaboration and decision support (n = 11).

	Subcategory	Code		
I	Communicating with other professionals	Value good communication with other professionals, such as nurses Make opportunities to hold discussions with multiple professionals		
2	Gathering information from other professionals	Obtain information from nurses about family background and family support Obtain information about the patients' thoughts and intentions from other professionals		
		Obtain information about the patients' social background from other professionals Obtain information about the patient's ADL status from other professionals		
3	Providing information to other professionals	Explain the patient's prognosis and future treatment plans to other professionals Explain the concerns of the patient's family to other professionals		
4	Managing the entire medical team	Manage the medical team, in which hematologists make comprehensive decisions based on information from other professionals Create a support system for patients		
5	Encouraging nurses to actively participate in the patient's decision-making	Encourage nurses to participate in the patients' decision-making Confirm whether there is any additional information or thoughts to convey to nurses during discussions about treatment decisions with the patient		

ADL = Activities of Daily Living.

Table 4.	Expected	roles of	other pro	ofessionals	in decision	support	(n =	11).	
----------	----------	----------	-----------	-------------	-------------	---------	------	------	--

Subcategory	Code	n		
Sharing patient information and care routines	Listen to the patients' thoughts and wishes and communicate them to the doctor Suggest knowledge that doctors may not know and explain how to care for patients in the right way			
	Point out the problems patients have with treatment decisions	2		
Sharing information from the treatment discussion	Attend treatment discussions and understand the patients' feelings and situation together	4		
	Read records of the process of informed consent and share the information	Ι		
Providing patients and their families with emotional support	Support the emotions of patients and their families	4		
Assembling a medical team that understands hematological malignancy	Work to ensure that the medical team understands hematological malignancy	I		

intentions. They also said that they would decide what information to convey and carefully explain the treatment and medical condition, without using jargon, so that the patient and family could easily understand. ASCO guidelines recommend that physicians provide information that takes into account individual patient interests and preferences.⁷ Although the present results are data obtained before these guidelines were developed, the hematologists who participated in this study were taking the actions recommended in the guidelines. The present results reveal more specific behaviors of hematologists with regard to what is recommended in the guidelines. For patients facing complex and risky treatment choices, it is important for hematologist to select information according to the patient's wishes and to convey information in easy-to-understand terms.

Hematologists were expected other professionalsto pay attention to the emotional aspects of the patient and family to minimize their anxiety. In addition, they expected nurses and other professionals to listen to the patient and family's wishes and thoughts about treatment, share them with the physician, and serve as emotional support for the patient and family. Moreover, hematologists were expected to understand the patient's wishes and preferences, explain complex and difficult-to-understand treatments and medical conditions, and present options that were consistent with the patient's wishes. ASCO guidelines also emphasize the need to form a rapport with patients and their families and to assess and support coping needs.⁷ The hematologists who participated in this study wanted to implement this in collaboration with other professionals. The wishes and intentions of patients and their families change as the disease progresses or symptoms worsen. Therefore, it is thought that by having physicians and other professions work together to understand the wishes of patients/families at that time, decision-making support in accordance with the wishes of patients/families will become possible.

Leukemia and lymphoma may be treated through chemotherapy, even in cases of relapse and during the refractory phase. This makes it difficult to determine when to transition from curative treatments to those more focused on quality of life (QOL).^{13,14} Previous studies have reported that hematologists are reluctant to discuss EOL issues while primary disease treatments are still possible.^{15,16} A number of the hematologists who participated in the study had a variety of ways of explaining the prognosis to patients and their families. For example, in some cases, they informed the family about the possibility of a sudden change in prognosis, including specific figures, while in other cases, depending on the severity of the disease and the stage of life, they did not inform them of the prognosis at all or withheld the fact. Furthermore, more than half of the respondents stated that they would explain the treatment that they thought would be most beneficial to the patient.

A number of the hematologists who participated in this study also had a long history of working with patients to

understand their individual backgrounds, and what they talked about and how they communicate, while also having a direction that the hematologists thought was suitable, and gave the patients some direction as they spoke. This suggested that hematologists attempt to tailor their decision-making support to the needs of their patients. On the other hand, hematologists infer patients' needs based on their previous experience, which runs the risk of making suggestions that are not in line with the patients' original needs. Previous studies have reported that hematologic oncology patients take a passive role in the treatment decision-making process due to the complexity of their treatment and disease¹⁷ and expect their physicians to take a paternalistic role.¹⁶ When hematologists provide some treatment direction and paternalistic response to hematologic oncology patients with these characteristics, patients may not fully understand the advantages and disadvantages of treatment and may not make an informed choice. If treatment is responded to, the patient's quality of life improves, but if treatment is not effective, the patient may die in the hospital during active treatment. In addition, patients may not be able to live the life they want, with increased risk of infection and prolonged hospitalization.¹ Hematologists need to have frank discussions with patients, keeping in mind the direction they think is best for the patient, and working with other professionals to understand the patient's wishes.

Hematologists who participated in this study indicated that the role they expected of multidisciplinary professionals was to inform them about patient thoughts, information, and methods of care that the physicians were unaware of. They also expected other professions to play a role in providing emotional support to patients and their families. In a previous study of oncologists, including hematologists, lack of information about the patient was the most frequently cited factor hindering patient involvement in decision-making.¹⁸ Physicians also recognized that having a third party present during decision-making discussions supported patient decisionmaking and facilitated involvement and reflection on treatment decisions.¹⁸ In that previous study, physicians emphasized the importance of obtaining information about the patient and the presence of a third party in the decision-making situation, which was similar to the findings of the present study. This confirms the importance of a multidisciplinary approach to facilitate decision-making in accordance with the patient's wishes. In making treatment decisions, it is necessary to organize information not only from a medical perspective, but also based on the patient's priorities and values. Obtaining such information is difficult for hematologists alone, and multidisciplinary collaboration is important. By understanding the patient's needs and organizing the information necessary for decision-making, it is expected that the discussion between the attending hematologist and the patient will be deepened.9

Finally, it is important to note that the survey for this study was conducted in 2011 and there was not much collaboration with the palliative care team,¹⁵ the participants in this study

did not mention the role they expected to play regarding palliative care physicians. Recently, however, the effects of early palliative care have been reported in clinical hematologic oncology. A study evaluating the effects of early introduction of palliative care and continuous psychological support by a multidisciplinary team in patients with acute leukemia reported a reduction in symptoms due to acute stress reactions compared to the usual care group.¹⁹ It has also been reported that patients undergoing hematopoietic stem cell transplantation who received regular twice-weekly visits by a palliative care physician had a higher QOL at 3 months of hospitalization compared to the group that received usual care.²⁰ In patients with leukemia and lymphoma, where the potential for rapid change is high, it is expected that hematologists and palliative care specialists will support patients and begin discussing long-term goals early, in case treatment goals suddenly change.²¹

This study had some limitations. The first is that the data collection and analysis were conducted between 2011 and 2012. Therefore, because treatment outcomes for hematologic tumors have improved compared to a decade ago, the data cannot be directly applied to decision support for patients with such tumors and their families today. However, the patients with treatment-resistant hematologic tumors have not changed significantly in their characteristics or treatment environment,^{1,22} and it is significant to clarify the hematologist's role in decision support. Second, the use of the opportunistic sampling makes it difficult to generalize the findings. In this study, we collected the opinions of hematologists at hospitals where hematologic oncology patients are mainly treated, such as cancer hospitals and university hospitals in Japan, and we believe that we were able to collect diverse opinions regarding the role of decision support as perceived by hematologists. Based on the present study, research is needed to clarify the decision support roles of other professionals who care for patients with leukemia and lymphoma, including nurses. This would make it possible to construct a model of shared decision-making support for hematologic oncology patients through multidisciplinary collaboration.

Appendix

Abbreviations

ASCO:	American Society of Clinical Oncology
EOL:	End-of-life
IC:	Informed consent
QOL:	Quality of life

Acknowledgments

The authors would like to thank Mizuki Takegata for her help in checking the coding. We would like to thank all of the hematologists who took part in the interviews who were willing to share their experiences of taking part in this study. We would also like to thank Professor Kiyoshi Miyagawa for his efforts in preparing this study. In addition, we thank Research Square for publishing this paper as a preprint. Qualitative analysis of the roles of physicians and nurses in providing decision support to patients with relapsed or refractory leukemia and malignant lymphoma | Research Square

Authors' Contributions

Miharu Morikawa and Yuki Shirai contributed to the design and implementation of the research and to the analysis of the results. Miharu Morikawa wrote the article in consultation with Yuki Shirai.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the JSPS KAKENHI: Grant Numbers JP19H03932 and JP23792581.

Ethics Approval

This study was approved by the Institutional Review Board of University of Tokyo (Approval No. 3443). The study was initiated at the University of Tokyo and completed at Kyoto University.

ORCID iD

Miharu Morikawa D https://orcid.org/0000-0003-4011-7628

Supplemental Material

Supplemental material for this article is available online.

References

- Odejide OO, Salas Coronado DYS, Watts CD, Wright AA, Abel GA. End-of-life care for blood cancers: A series of focus groups with hematologic oncologists. *J Oncol Pract.* 2014;10(6): e396-e403. doi:10.1200/JOP.2014.001537
- Odejide OO, Cronin AM, Condron NB, et al. Barriers to quality end-of-life care for patients with blood cancers. *J Clin Oncol.* 2016;34(26):3126-3132. doi:10.1200/JCO.2016.67.8177
- Rood JAJ, Eeltink CM, van Zuuren FJ, Verdonck-de Leeuw IM, Huijgens PC. Perceived need for information of patients with haematological malignancies: a literature review. *J Clin Nurs*. 2015;24(3-4):353-369. doi:10.1111/jocn.12630
- Ernst J, Kuhnt S, Schwarzer A, et al. The desire for shared decision making among patients with solid and hematological cancer. *Psycho Oncol.* 2011;20(2):186-193. doi:10.1002/pon.1723
- Shirai Y, Kawa M, Miyashita M, Kazuma K. Nurses' perception of adequacy of care for leukemia patients with distress during the incurable phase and related factors. *Leuk Res.* 2005;29(3): 293-300. doi:10.1016/j.leukres.2004.07.009
- 6. LeBlanc TW, Fish LJ, Bloom CT, et al. Patient experiences of acute myeloid leukemia: A qualitative study about diagnosis,

illness understanding, and treatment decision-making. *Phy-choonlcogy*. 2017;26(12):2063-2068. doi:10.1002/pon.4309

- Ferrell BR, Temel JS, Temin S, et al. Integration of palliative care into standard oncology care: American Society of Clinical Oncology clinical practice guideline update. *J Clin Oncol.* 2017; 35(1):96-112. doi:10.1200/JCO.2016.70.1474
- Artioli G, Ghirotto L, Alquati S, Tanzi S. Behavioral patterns in breaking bad news communication: an ethnographic study with hematologists. *Int J Environ Res Public Health*. 2022;19(5): 2585. doi:10.3390/ijerph19052585
- Randall TC, Wearn AM. Receiving bad news: patients with haematological cancer reflect upon their experience. *Palliat Med.* 2005;19(8):594-601. doi:10.1191/0269216305pm10800a
- Ishida DN, Toomata-Mayer TF, Braginsky NS. Beliefs and attitudes of Samoan women toward early detection of breast cancer and mammography utilization. *Cancer.* 2001;91(1suppl1):262-266
- McClure KB, Delorio NM, Schmidt TA, Chiodo G, Gorman P. A qualitative study of institutional review board members' experience reviewing research proposals using emergency exception from informed consent. *J Med Ethics*. 2007;33(5): 289-293. doi:10.1136/jme.2005.014878
- Krippendorff K. Content analysis. International Encyclopedia of Communication. 1989;1:403-407
- Chung HM, Lyckholm LJ, Smith TJ. Palliative care in BMT. Bone Marrow Transplant. 2009;43(4):265-273. doi:10.1038/ bmt.2008.436
- Epstein AS, Goldberg GR, Meier DE. Palliative care and hematologic oncology: The promise of collaboration. *Blood Rev.* 2012;26(6):233-239. doi:10.1016/j.blre.2012.07.001
- 15. Morikawa M, Shirai Y, Ochiai R, Miyagawa K. Barriers to the collaboration between hematologists and palliative care teams on relapse or refractory leukemia and malignant lymphoma

patients' care: A qualitative study. *Am J Hosp Palliat Care*. 2016;33(10):977-984. doi:10.1177/1049909115611081

- Ernst J, Berger S, Weißflog G, et al. Patient participation in the medical decision-making process in haemato-oncology – a qualitative study. *Eur J Cancer Care*. 2013;22(5):684-690. doi: 10.1111/ecc.12077
- Ernst J, Weissflog G, Brähler E, Niederwieser D, Körner A, Schröder C. Participation of haemato-oncological patients in medical decision making and their confidence in decisions. *Eur J Cancer Care*. 2011;20(4):534-538. doi:10.1111/j.1365-2354. 2010.01219.x
- Shepherd HL, Tattersall MHN, Butow PN. Physician-identified factors affecting patient participation in reaching treatment decisions. *J Clin Oncol*. 2008;26(10):1724-1731. doi:10.1200/ JCO.2007.13.5566
- Rodin G, Malfitano C, Rydall A, et al. Emotion And Symptomfocused Engagement (EASE): a randomized phase II trial of an integrated psychological and palliative care intervention for patients with acute leukemia. *Support Care Cancer*. 2020;28(1): 163-176. doi:10.1007/s00520-019-04723-2
- El-Jawahri A, LeBlanc T, VanDusen H, et al. Effect of inpatient palliative care on quality of life 2 weeks after hematopoietic stem cell transplantation: A randomized clinical trial. *JAMA*. 2016;316(20):2094-2103. doi:10.1001/jama.2016.16786
- El-Jawahri A, LeBlanc TW, Kavanaugh A, et al. Effectiveness of integrated palliative and oncology care for patients with acute myeloid leukemia A randomized clinical trial. *JAMA Oncol.* 2021;7(2):238-245. doi:10.1001/jamaoncol.2021.0709
- Prod'homme C, Jacquemin D, Touzet L, Aubry R, Daneault S, Knoops L. Barriers to end-of-life discussions among hematologists: A qualitative study. *Palliat Med.* 2018;32(5):1021-1029. doi:10.1177/0269216318759862